Zymeworks Q1 net loss $44.2M; Jazz's zanidatamab sBLA accepted with Priority Review, PDUFA Aug 25, 2026

Zymeworks Inc.

2026-Q1 EPS reported -$0.59 revenue$2,408,000

Jazz sBLA for zanidatamab in 1L HER2+ GEA accepted with Priority Review; PDUFA target date Aug 25, 2026.
Upon US FDA approval, Zymeworks eligible for $250M milestone from Jazz; $15M from BeOne for China approval.
Q1 2026 revenue $2.4M (down 91% YoY from $27.1M); net loss $44.2M vs $22.6M loss in Q1 2025.
Cash and marketable securities $403.8M as of Mar 31, 2026; $95.8M used for share repurchases under $125M program.
ZW191 Phase 1 data at AACR: 56% ORR in PROC, 61% in ovarian, 57% in endometrial; FDA Fast Track granted.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zymeworks Inc. reported financial results for the first quarter March 31, 2026 (three months ended March 31, 2026).

Period: the first quarter March 31, 2026 (three months ended March 31, 2026)
Result: reported results

Exact text from the filing

On May 7, 2026, Zymeworks Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-26-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.